

# An Aseptic Processing Update: Industry and Regulatory Trends The Path Forward

PDA Southern California Chapter  
Aseptic Processing and Sterilization  
Symposium November 2019

Hal Baseman  
Chief Operating Officer  
ValSource Inc.


# A Call to Action

There is a need and opportunity for **improvement** in the manufacture of sterile biopharmaceutical products.

1. **Aseptic processing is here to stay**
2. **Traditional process control methods may not be sufficient**
3. **We are not changing fast enough**

# Part 1: Updates

# Update: Annex 1 Manufacture of Sterile Medicinal Products



## Update: Annex 1 revision general highlights

- Improved document, but retains lower value control expectations
- Sets expectation for use of quality risk management principles, but needs to do more for alternative approaches
- Misses opportunity to modernize and harmonize terms

# Update: Annex 1 revision specific highlights

- Sterile filtration: positioning and PUPSIT
- APS acceptance criteria, operator qualification, duration
- Isolator barriers: unidirectional airflow, settling plates, glove IT, sterilization of indirect contact surfaces
- 5  $\mu$  classification and monitoring
- Disinfectant rotation
- Container closure integrity testing
- WFI distribution temperature, steam generation, moist heat sterilization

# Why is the Annex 1 Revision Important?

First new discussion on aseptic processing in a while

*Proposed revision to EMA Annex 1 contained 43 recommendations for risk-based approaches to sterile product manufacturing and control.*

## Why is Annex 1 and QRM important?

*If regulators expect industry to use QRM to justify current approaches ... then QRM can be used to justify new approaches.*



# Update: Pre-Use, Post Sterilization Integrity Test

Filter flaws from lack of mft./user controls

Product clog/blind filter flaws

Test Controls

Determine conditions

Provide evidence

Mft./User FTA risk Assessments

Masking Studies

BCT Data Mining

## Regulator Concerns

Predetermined Outcome Risk Assessments

PUPSIT not risk or Burden

Change focus to Product quality

Fill Scientific Evidence Gap

Provide evidence of complexity

SF-QRM Focus

## Workstream

PUPSIT Best Practice PtC

PUPSIT FMEA

Industry Surveys

# Update: Pre-Use, Post Sterilization Integrity Test

Filter flaws from lack of mft./user controls

Product clog/blind

Test Controls

Determine conditions

Mft./User FTA risk Assessments

Masking Studies

BCT Data

**Provide industry and regulators with guidance to make informed decisions.**

Reg

Predetermined Outcome Risk Assessments

Change focus to

**Fill Scientific Evidence Gap**

Workstream

PUPSIT Best Practice PtC

PUPSIT FMEA

PUPSIT not risk or Burden

Provide evidence of complexity

Industry Surveys

## **Part 2: Moving Forward**

# Changing business ...

1. New therapies
2. Drug supply and public health
3. Business aspects of quality and manufacturing reliability
4. New technology
- 5. Competition for technical talent**

# Attracting new talent

Restaurant industry	66	25	8	+58
Computer industry	61	28	11	+50
Grocery industry	58	27	15	+43
Farming and agriculture	58	24	17	+41
Travel industry	52	35	13	+39
Accounting	45	45	9	+36
Automobile industry	53	29	18	+35
Retail industry	50	28	19	+31
Real estate industry	49	31	19	+30
Banking	50	25	25	+25
Electric and gas utilities	47	28	24	+23
Sports industry	45	29	25	+20
Airline industry	42	32	23	+19
Telephone industry	42	32	26	+16
Publishing industry	39	36	24	+15
Internet industry	43	26	30	+13
Movie industry	41	31	28	+13
Education	45	18	35	+10
Television and radio industry	40	27	32	+8
The legal field	35	34	30	+5
Oil and gas industry	39	25	36	+3
Advertising and public relations industry	33	32	34	-1
Healthcare industry	38	14	48	-10
The federal government	25	23	52	-27
<b>Pharmaceutical industry</b>	<b>27</b>	<b>15</b>	<b>58</b>	<b>-31</b>

GALLUP, AUG. 1-14, 2019

## Desired state: What if we were able to ...

### **continuously manufacture aseptically processed sterile products,**

- without reliance on human intervention, unidirectional airflow, viable environmental monitoring,
- release those products parametrically, in real time, without sterility testing,
- based on ...
  - ✓ well engineered process design,
  - ✓ fully automated equipment,
  - ✓ contamination-protected critical zones,
  - ✓ complete process understanding,
  - ✓ indisputable correlation of data and outcome

**Suppose we call it a 100 year project**

# Sterile Biopharmaceutical Manufacturing Today and Tomorrow

KEY ELEMENTS	YESTERDAY & TODAY	TOMORROW
<b>Process</b>	Batch driven, single shift, intervention laden, personnel dependent, environment constrained	Continuous, small closed environment, automated, data driven and controlled, standardized
<b>Control</b>	Test, monitor, demonstrate, lagging, excursion and deviation investigation, reactive, corrective	Design driven, line of sight, risk-based, scientific, data, leading, predictive, preventive
<b>Sterility Assurance</b>	Parameter based, anecdotal, product and process testing, compliance risk, subjective	Quality attribute based, statistical evaluation, trend analysis, science/risk awareness, unbiased, objective
<b>Communication</b>	Lack of transparency, reluctance to share experience, failures, criteria for success	Exchange of ideas, information, results, failures, remedies, criteria for success
<b>Cooperation</b>	Conflict relationship between manufacturers, suppliers, and regulators, blurring roles and responsibilities, regulatory risk concern	Partnership of manufacturers, suppliers, and regulators with defined roles and responsibilities

## Part 3: Thoughts to consider ...



# The manufacturing intelligence revolution is here ...

1. Digital clone facilities and modeling
2. Predictive maintenance and machine learning
3. Data linked environmental and process trending
4. Data driven parametric release
5. Virtual reality training
6. Visual SOPs and instructions
7. Mission control centers

## ... are we ready?

- Will the increase in data outpace process understanding?
- How will we react to increased data and process awareness?
- How will validation change?


# We need to .... reduce complexity

Smaller, scalable, standardized critical areas are less complex, less variable, lower the cost, with less contamination risk

## ... design better isolator processes

1. Aseptic technique and practice remain important
2. Re-define decontamination
3. Establish operations based design and control criteria

# ... change emphasis of validation



# ... challenge testing as a contamination control strategy

- Excursions have different risks
- Evaluation of the trend more useful than detecting excursions
- Understand capability and limitations of control strategies
- Improper reaction can desensitize or distract

Proactive  
Leading




Process Design  
Validation  
Monitoring  
Product Testing



Reactive  
Lagging

# ... think critically about aseptic process validation

Does the aseptic process simulation \_\_\_\_\_ ?

- X **Judge** if process effective
- X **Qualify** personnel or demonstrate proficiency
- X **Validate** interventions
- X **Establish** holding times, filling durations or conditions
- X **Simulate** effect of fatigue on performance
- X **Allow** for disruptions
- X **Verify** decontamination process
- X **Confirm** filling system acceptability
-  **Uncover** weakness in the process

## ... search for the science

- Why are doing this? **Validate the aseptic process**
- What is the objective? **Sterility assurance**
- How does it accomplish the objective?
- Is it scientifically valid and useful?
- What is the harm?
- Is there a better way?

Efforts of no value divert resources from efforts of value.



## ... ponder APS questions

- Are interventions included at production frequency?
- Does APS establish production duration?
- Do media fills qualify filler parts?
- Should intervention rejects be incubated?
- Must personnel qualification involve APS participation?
  - Why?
  - Objective?
  - Accomplished?
  - Good science?
  - Harm?
  - Better way?

## Traditional approach

- Personnel and interventions qualified with APS

## Alternate approach

- Separate out personnel and process qualification

... focus on “value of quality” rather than “cost of quality”

Quality and profit are not mutually exclusive, conflicting objectives

## ... embrace le grand partenariat

Technology and innovation based improvement cannot be realized without a partnership of manufacturers, regulators, and suppliers

- Each must accept its unique role
  - **Manufacturers** identify needs
  - **Suppliers** provide solution to need
  - **Regulators** judge acceptability of solution
  - Patients benefit

# Update: PDA Related Efforts

## Annex 1 Revision

Aseptic Process PtC Part 1 & 2 (3?)  
Isolator PtC and revisions to TR 13, 22, 34  
QRM Standard for Aseptic Processing  
December 2019 QRM Workshops  
Second round of Annex 1 commenting  
Interpretation of Annex 1 revision education  
PDA/BPOG SFQRM collaboration

## Aseptic Processing Future State

MSOP initiatives in RT release,  
manufacturing intelligence,  
and standardization  
TRI C&GT education

Challenge the status quo. Ask WHY and WHY NOT?

*If everyone is thinking the same way, then  
not everyone is thinking...*